Dr. Daniele Gilkes is assistant professor of oncology, as well as an assistant professor in chemical and molecular engineering at the Johns Hopkins University School of Medicine.
This is her first year as a BCRF grantee. Dr. Paul Macklin is an associate professor of intelligent systems engineering, and a member of the Melvin & Bren Simon Cancer Center at Indiana University.
He’s a BCRF grantee since 2014. Together, Drs. Gilkes and Macklin are part of a collaboration between the BCRF and JKTG Foundation that links computational scientists with biologists.
They recently talked to BCRF about their efforts to gain new insights into tumor growth, metastasis, and the mechanics of drug resistance.
Featured news
Applying nanoparticles and the immune system to fight cancer
JKTG-funded research, Iron oxide nanoparticles inhibit tumor progression and suppress lung metastases in mouse models of breast cancer, appears in the journal ACS Nano and features a collaboration between researchers at Johns Hopkins University School of Medicine and the Hormel Institute at the University of Minnesota.
Ted’s Take: It’s about the money
Money is what seems to drive things and money is what seems to drive organizations too. They all start with an overriding moral goal but after a while things often turn toward more money.
Ted’s Take: The best patient advocate? You.
When you’re a patient, you are kind of vulnerable. You have a problem, are often sketchy about what it is and the potential treatment or therapy needed. The bigger the problem, the more vulnerable you are. This makes you a perfect advocate.
Jayne Koskinas Ted Giovanis
Foundation for Health and Policy
PO Box 130
Highland, Maryland 20777
Media contact: 202.548.0133